chicagoest - The $2.75 to $6.00 that I used in my matrix is the same pricing for ABL that the company used in their presentations 4 to 6 years ago when they were saying it was worth $2,000 to $5,000 per year based on the Number Needed to Treat. The pricing is based on chronic use for CVD not based on COVID use. 

The good part for the shareholders is that any company that wants to take us out has the ability to price it wear ever they want to justify the price they are willing to pay us.

tada